Your SlideShare is downloading. ×
0
New indication for old drug<br />
A new indication for old drug<br />Ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indol...
A new target<br />MC-101 inhibits <br />protein kinase C alpha (PKCα)<br />
A new target<br />The same specificity shows major metabolite МС-109<br />
MC-101 inhibits NFkappaB<br />
A possible role of MC-101 in inflammation process<br />МС-101<br />Pic. from «Targeting the NF-κB pathway in asthma and ch...
A possible role of MC-101 in inflammation process<br />МС-101<br />Pic. from Targeting the NF-κB pathway in asthma and chr...
The most promising new indication for MC-101 is asthma<br />MC—101 shows anti-inflammatory activity.<br />Viral infections...
Asthma animal model<br />MC-101 was evaluated for possible inhibition of airway hyperresponsiveness in mice. The ovalbumin...
Respiratory parameters measured by whole body plethysmography<br />
Respiratory parameters measured by whole body plethysmography<br />
Complex indexPehnfor evaluation of respiratory parameters<br />
МС-101 reduces bronchoconstriction <br />
MC-101 reduces quantity of lymphocytes in BALF<br />
Especially eosinophils<br />
Also MC-101 reduces concentration of proinflammatory cytokines<br />
Also MC-101 reduces concentration of proinflammatory cytokines<br />
Anti-asthmatic potency of MC-101<br />An open-label stratified randomized parallel group study conducted at the Pulmonolog...
Trial groups<br />The experimental group (12 patients) – Arbidol® 100 mg twice a day plus short acting beta agonists (SABA...
Trial targets<br />Reduction of asthma attack quantity<br />Improvement of spirography parameters<br />Reduction of medium...
Groups description<br />
Measurement of peak flow and spirographyin experimental group(Wilkinson criteria)<br />
Measurement of peak flow and spirographyin control group (Wilkinson criteria)<br />
Measurement of peak flow and spirographyin comparator group (Wilkinson criteria)<br />
Dynamics of frequency of asthma attacks <br />Number of patients<br />Administration of Arbidol and Syngularreduce frequen...
Dynamics of frequency of SABA inhalations <br />Administration of Arbidol and Syngularreduce frequency <br />of SABA inhal...
Results<br />Oral administration of MC-101 in the dose of 100 mg twice a day within 28 days improves clinical course of br...
Upcoming SlideShare
Loading in...5
×

New indication for old drug

315

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
315
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "New indication for old drug"

  1. 1. New indication for old drug<br />
  2. 2. A new indication for old drug<br />Ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate is widely used in Russia for prevention and treatment of flu and other viral infections. <br />26,35 million of packs of Arbidol® were sold in 2008 . <br />
  3. 3. A new target<br />MC-101 inhibits <br />protein kinase C alpha (PKCα)<br />
  4. 4. A new target<br />The same specificity shows major metabolite МС-109<br />
  5. 5. MC-101 inhibits NFkappaB<br />
  6. 6. A possible role of MC-101 in inflammation process<br />МС-101<br />Pic. from «Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease» M.R. Edwards et al. / Pharmacology & Therapeutics 121 (2009) 1–13<br />
  7. 7. A possible role of MC-101 in inflammation process<br />МС-101<br />Pic. from Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease M.R. Edwards et al. / Pharmacology & Therapeutics 121 (2009) 1–13<br />
  8. 8. The most promising new indication for MC-101 is asthma<br />MC—101 shows anti-inflammatory activity.<br />Viral infections cause more than half of all cases of asthma attacks. MC-101 has a huge advantage because of its antiviral activity.<br />
  9. 9. Asthma animal model<br />MC-101 was evaluated for possible inhibition of airway hyperresponsiveness in mice. The ovalbumin (OVA)-sensitized animals, 10 animals per group, were challenged by nasal inhalation with aerosolized 5% OVA for 25 min on Days 21, 23, and 25. The mice received vehicle, reference standard (Dexamethasone, 3 mg/kg) or MC-101 by gavage (PO) once daily from day 21 to day 26, preceding<br />ovalbumin aerosol challenge by 60 min on days 21, 23 and 25 as well as methacholine challenge on day 26. Noninvasive measurements of airway responsiveness were performed by using whole body plethysmography, using increases in enhanced pause (Penh) as an index of airway obstruction. Responses to inhaled methacholine were measured and calculated as percentage of respective baseline values. <br />MC-101<br />Dexametasone<br />
  10. 10. Respiratory parameters measured by whole body plethysmography<br />
  11. 11. Respiratory parameters measured by whole body plethysmography<br />
  12. 12. Complex indexPehnfor evaluation of respiratory parameters<br />
  13. 13. МС-101 reduces bronchoconstriction <br />
  14. 14. MC-101 reduces quantity of lymphocytes in BALF<br />
  15. 15. Especially eosinophils<br />
  16. 16. Also MC-101 reduces concentration of proinflammatory cytokines<br />
  17. 17. Also MC-101 reduces concentration of proinflammatory cytokines<br />
  18. 18. Anti-asthmatic potency of MC-101<br />An open-label stratified randomized parallel group study conducted at the Pulmonology Research Institute (Moscow, Russia) under the direction of Prof. Alexander Chuchalin, President of Russian Association of Pulmonologists. The purpose was to evaluate anti-asthmatic potency of MC-101. <br />
  19. 19. Trial groups<br />The experimental group (12 patients) – Arbidol® 100 mg twice a day plus short acting beta agonists (SABA)<br />The comparator group (12 patients) - Singular® 10 mg once a day plus short acting beta agonists (SABA)<br />The control group (12 patients) – short acting beta agonists (SABA)<br />
  20. 20. Trial targets<br />Reduction of asthma attack quantity<br />Improvement of spirography parameters<br />Reduction of medium SABA dose.<br />
  21. 21. Groups description<br />
  22. 22. Measurement of peak flow and spirographyin experimental group(Wilkinson criteria)<br />
  23. 23. Measurement of peak flow and spirographyin control group (Wilkinson criteria)<br />
  24. 24. Measurement of peak flow and spirographyin comparator group (Wilkinson criteria)<br />
  25. 25. Dynamics of frequency of asthma attacks <br />Number of patients<br />Administration of Arbidol and Syngularreduce frequency of asthma attacks <br />
  26. 26. Dynamics of frequency of SABA inhalations <br />Administration of Arbidol and Syngularreduce frequency <br />of SABA inhalations <br />
  27. 27. Results<br />Oral administration of MC-101 in the dose of 100 mg twice a day within 28 days improves clinical course of bronchial asthma of light and average severity, reducing the frequency of asthma attacks and requirement of using of short acting beta agonists. Effectiveness of the drug was shown by the measurement of peak flow and spirography (FVC, FEV1, FEV1%). <br />No negative side effects have been revealed.<br />
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×